Publications
5674 Results
- Journal / Conference
- J Clin Oncol 35, 2017 (suppl; abstr 9500); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presenation
- Year
- 2017
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609
A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-a2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms
- Journal / Conference
- J Clin Oncol 35 (suppl; abstr 9055); ASCO Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
- Year
- 2017
- Research Committee(s)
- Lung
- Study Number(s)
- S1400D
Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGFR pathway-activated stage IV squamous cell lung cancer (sqNSCLC): lung-map sub-study SWOG S1400D
- Journal / Conference
- Journal of Clinical Oncology Mar 10;35(8):885-892
- Year
- 2017
- Research Committee(s)
- Melanoma
- PMID
- PMID28135150
- PMC
- PMC5455684
- Study Number(s)
- CTSU/E1697
Phase III randomized study of 4 weeks of high-dose interferon-a-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E1697)
- Journal / Conference
- Journal of Thoracic Oncology Aug;12(8):1299-1308; Jun 6 [Epub ahead of print]
- Year
- 2017
- Research Committee(s)
- Lung
- PMID
- PMID28599887;PMC5690479
- Study Number(s)
- S0905
Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)
- Journal / Conference
- Journal of Clinical Oncology Sep 1;35(25):2885-2892
- Year
- 2017
- Research Committee(s)
- Lung
- PMID
- PMID28493811
- PMC
- PMC5578390
- Study Number(s)
- S0023
A pooled analysis of individual patient data of concurrent chemoradiotherapy for stage 3 non-small-cell lung cancer in elderly patients compared to younger patients who participated in United States National Cancer Institute Cooperative Group studies
- Journal / Conference
- Blood Mar 30;129(13):1763-1767
- Year
- 2017
- Research Committee(s)
- Leukemia and Lymphoma
- PMID
- PMID28082441
- PMC
- PMC5374291
- Study Number(s)
- C9710, E2496, S0521
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era
- Journal / Conference
- Journal of the National Cancer Institute, Apr;109(4). pii: djw239.
- Year
- 2017
- Research Committee(s)
- Early Therapeutics and Rare Cancers and Head and Neck
- PMID
- PMID27927756
- PMC
- PMC6059121
- Study Number(s)
- SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)
Surrogate endpoints for overall survival in loco-regionally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis
- Journal / Conference
- Journal of Clinical Oncology, Feb 35(5):499-505
- Year
- 2017
- Research Committee(s)
- Early Therapeutics and Rare Cancers and Head and Neck
- PMID
- PMID27918720
- PMC
- PMC5791836
- Study Number(s)
- SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)
What is the best treatment for locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis
- Journal / Conference
- Leukemia & Lymphoma Aug;58(8):1814-1822
- Year
- 2017
- Research Committee(s)
- Lymphoma
- PMID
- PMID27967294
- PMC
- PMC5502834
- Study Number(s)
- E4494
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)
- Journal / Conference
- International Conference on Malignant Lymphoma (June 14-17, 2017, Lugano, Switzerland), oral
- Year
- 2017
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0816